Wedbush Morgan Reiterates a 'Buy' on Biodel (BIOD)
BIOD Hot Sheet
Rating Summary:3 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Wedbush Morgan reiterates a 'Buy' on Biodel (Nasdaq: BIOD). Price target $10.
Wedbush analyst says, "Management guided to announcing VIAject regulatory announcement in March. We believe a transforming VIAject partnership announcement could follow in 2009. We anticipate other catalysts in 2009."
Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut.
Wedbush analyst says, "Management guided to announcing VIAject regulatory announcement in March. We believe a transforming VIAject partnership announcement could follow in 2009. We anticipate other catalysts in 2009."
Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut.
You May Also Be Interested In
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Barclays on U.S. Specialty Pharmaceuticals: Model Updates on FRX, MRX, WCRX & PCRX
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Wedbush MorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
